Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7227166 |
Synonyms | |
Therapy Description |
RO7227166 is a bispecific antibody that targets both CD19 and TNFRSF9 (4-1BB), potentially resulting in enhanced anti-tumor immune response (Blood (2022) 140 (Supplement 1): 9461-9463). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7227166 | RO 7227166|RO-7227166|Ensomafusp Alfa|RG6076|RG-6076|RG 6076|Englumafusp Alfa | CD19 Antibody 21 TNFRSF9 Antibody 32 | RO7227166 is a bispecific antibody that targets both CD19 and TNFRSF9 (4-1BB), potentially resulting in enhanced anti-tumor immune response (Blood (2022) 140 (Supplement 1): 9461-9463). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|